Dihexa

Dihexa is a synthetic oligopeptide derivative, chemically N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, developed as a candidate treatment for neurodegenerative disease. It belongs to a series of small molecules built from angiotensin IV, a fragment of the brain's renin-angiotensin system long recognized to carry procognitive properties ^[2]. The parent peptides were poor drug candidates because they were rapidly broken down and could not cross the gut wall or the blood-brain barrier; chemists at Washington State University, led by Joseph Harding and John Wright, therefore modified the three N-terminal amino acids of the active peptide to produce an orally active, metabolically stable, blood-brain-barrier-permeable analog, which they named Dihexa ^[1].

Research on Dihexa has centered on its ability to restore memory and rebuild synapses. In rodent models it reversed the cognitive deficits caused by the amnestic drug scopolamine and those seen in aged animals, while promoting the growth of new dendritic spines and functional synapses in the hippocampus ^[1]. Independent work in APP/PS1 transgenic mice, a model of Alzheimer's disease, reported that Dihexa improved spatial learning, increased synaptic proteins, and reduced brain inflammation ^[3]. Its activity is closely tied to the hepatocyte growth factor (HGF) and its receptor c-Met, a growth-factor system so central to the molecule that stem-cell researchers use Dihexa as a substitute for HGF when differentiating cells in the laboratory ^[4][5].

Dihexa is an investigational research compound; it is not an approved drug and is not a dietary supplement, and it is sold as a research chemical, usually as a powder. It has been examined primarily in the context of Alzheimer's and Parkinson's disease, and the broader angiotensin IV analog program it came from has informed the development of related clinical candidates aimed at augmenting synaptic connectivity ^[2].

Human safety data for Dihexa as sold does not exist. No published toxicology, no long-term safety study in any species, and no human trial of the molecule itself.

Principal mechanistic concern: MET is a proto-oncogene and HGF/MET overactivation drives proliferation, invasion and metastasis in multiple tumour types. A compound whose entire selling point is sustained potentiation of that system carries a theoretical cancer-promotion risk, flagged by the Alzheimer's Drug Discovery Foundation's Cognitive Vitality assessment. This risk has never been characterized experimentally for Dihexa. Note the internal contradiction in the originating literature: the same laboratory published that close chemical relatives were HGF/Met ANTAGONISTS with anticancer activity (PMID 21859930, PMID 22129598), and both of those papers are now retracted, so neither the pro-tumour nor the anti-tumour direction is established.

Prodrug safety, by injection, not oral Dihexa: fosgonimeton was reported safe and well tolerated in phase 1 with no drug-related adverse events. Across later trials the dominant adverse event was injection-site reaction, with roughly 22% of enrollees in one trial discontinuing because of it; no deaths or serious adverse events were reported overall, though the SHAPE trial in Parkinson's disease dementia and Lewy body dementia was terminated and raised safety questions in higher-dose groups.

Efficacy reality check: the entire clinical program on this mechanism failed. ACT-AD (phase 2) missed its primary endpoint, SHAPE (phase 2) was terminated, and LIFT-AD (phase 2/3, 554 subjects, topline September 2024) missed its primary endpoint and all key secondary endpoints for cognition and function. An independent preclinical study also found Dihexa ineffective in a Huntington's model (PMID 38489193).

Interactions: not studied in humans. Post-hoc analysis of ACT-AD suggested acetylcholinesterase inhibitors may antagonize the effect of the prodrug, which is a hypothesis-generating signal only.

Regulatory status: not approved as a drug in any jurisdiction, and not a lawful dietary supplement ingredient; it is sold as a research chemical. Dihexa acetate was nominated for FDA's 503A bulk drug substances list; FDA placed a group of peptides including it into Category 2 (significant safety risks identified, compounding not permitted) in September 2023, the nomination subsequently lapsed, and FDA has scheduled a Pharmacy Compounding Advisory Committee review of dihexa acetate for before the end of February 2027. WADA: Dihexa is not named explicitly on the Prohibited List, but because it is not approved for human therapeutic use by any government regulatory health authority it falls under S0 (Non-Approved Substances), prohibited at all times both in and out of competition; the HGF mechanism gives a further argument for capture under S2.3 (growth factors and growth factor modulators). Athletes should treat it as banned.

Dihexa was engineered by John W. Wright, Joseph W. Harding, and colleagues at Washington State University as part of a long program to turn the pro-cognitive activity of the brain peptide angiotensin IV into a usable drug. The parent peptides showed procognitive promise but failed pharmacokinetically, being neither orally active nor able to cross the blood-brain barrier; the team's solution was N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, an orally active, brain-penetrant analogue they named Dihexa.

In animal work published around 2013 to 2014, Dihexa reversed chemically and age-induced memory deficits and promoted the formation of new dendritic spines and functional synapses in the hippocampus, and the group linked its activity to the hepatocyte growth factor (HGF) and its receptor c-Met.

The compound was advanced toward development through the spin-out company M3 Biotechnology (later Athira Pharma), and it has since become one of the most discussed synaptogenic molecules in the nootropic community.

Dihexa enjoys an outsized reputation among cognitive-enhancement enthusiasts as a rare compound that appears to act on the machinery that physically rewires neural circuits rather than merely nudging neurotransmitter levels. Its appeal rests on striking preclinical reports of reversed amnesia, restored spatial learning in Alzheimer's-model mice, and measurable growth of new synapses, together with a purposeful design for oral activity and brain penetration. That distinctive synaptogenic angle has kept it prominent in both academic discussion and community circles. Honesty requires noting real caveats: the evidence remains preclinical, human safety and efficacy have not been established, potent synaptogenic activity invites questions about long-term effects, and a key mechanistic paper in the field was later retracted, so its promise, while genuine, is still unproven in people.